Igor Matushansky

Columbia University Irving Medical Center — United States

Medicine · Health Sciences

22h-index2.3kcitations72works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(19), Epigenetics and DNA Methylation(16), Virus-based gene therapy research(12), Viral Infections and Outbreaks Research(12), Histone Deacetylase Inhibitors Research(8)

Publications72 total

Dermatofibrosarcoma protuberans: A clinical review of diagnosis and management
Journal of the American Academy of Dermatology·2026
Supplementary Material for "Dermatofibrosarcoma protuberans: A clinical review of diagnosis and management"
Mendeley Data·2026Open Access
Supplementary Material for "Dermatofibrosarcoma protuberans: A clinical review of diagnosis and management"
Mendeley Data·2026Open Access
Supplementary Material for "Racial disparities in dermatofibrosarcoma protuberans: a retrospective cohort study"
Mendeley Data·2026Open Access
Supplementary Material for "Racial disparities in dermatofibrosarcoma protuberans: a retrospective cohort study"
Mendeley Data·2026Open Access
Racial disparities in dermatofibrosarcoma protuberans: A retrospective cohort study
Journal of the American Academy of Dermatology·2026
Progressive Metastatic Cutaneous TFCP2::FUS Fusion-Positive Rhabdomyosarcoma: A Case Report
Case Reports in Oncology·2025Open Access
UV-induced multifocal cutaneous high-grade leiomyosarcoma
BMJ Case Reports·2025
Data from Chromatin Structure Predicts Epigenetic Therapy Responsiveness in Sarcoma
2023Open Access
Data from Chromatin Structure Predicts Epigenetic Therapy Responsiveness in Sarcoma
2023Open Access
Supplementary Figures 1-11, Supplementary Tables 1-2 from Chromatin Structure Predicts Epigenetic Therapy Responsiveness in Sarcoma
2023Open Access
Supplementary Figures 1-11, Supplementary Tables 1-2 from Chromatin Structure Predicts Epigenetic Therapy Responsiveness in Sarcoma
2023Open Access
Abstract 2048: <i>In vitro</i> and <i>in vivo</i> characterization of non-oncolytic engineered arenavirus vectors for cancer immunotherapy
Cancer Research·2022
Abstract 4198: Evaluation of a cancer immunotherapy with engineered arenavirus vectors and 4-1BB agonists in a preclinical tumor model
Cancer Research·2022
Abstract 3284: HB-201 and HB-202, an arenavirus-based immunotherapy, induces tumor T cell infiltration in patients with HNSCC and other HPV16+ tumors
Cancer Research·2022· 6 cited
Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform
Frontiers in Oncology·2021· 20 citedOpen Access
961MO Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers
Annals of Oncology·2021· 1 cited
Abstract LB049: Preliminary analysis of <i>immunogenicity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with advanced HPV16-positive cancers</i>
Cancer Research·2021· 2 cited
First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers.
Journal of Clinical Oncology·2021· 7 cited
Abstract 4058: TheraT - a highly versatile arenavirus based vector platform for intravenous and intratumoral cancer immunotherapy
Cancer Research·2020· 2 cited
page 1 of 4Next →

Frequent Co-authors

Carlos Cordon‐Cardo(10), Robert G. Maki(9), Arthur I. Skoultchi(8), Klaus K. Orlinger(8), Elizabeth Charytonowicz(7), Joslyn Mills(7), Henning Lauterbach(6), Eva Hernando(5), Sara Siddiqi(5), Farshid Radparvar(5), Sarah Schmidt(5), Xiaoping Qing(5), Ursula Berka(5), Felix Stemeseder(5), Daniel D. Pinschewer(5), Nicholas D. Socci(4), Filemon S. Dela Cruz(4), Melissa Terry(4), Kia Katchar(4), Katia Schlienger(4)